Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results

المؤلفون المشاركون

Angeletti, Silvia
Afeltra, Antonella
Ciccozzi, Massimo
Margiotta, Domenico Paolo Emanuele
Navarini, Luca
Laudisio, Alice
Bisogno, Tiziana
Piccoli, Alessandra
Maccarrone, Mauro

المصدر

Journal of Immunology Research

العدد

المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-6، 6ص.

الناشر

Hindawi Publishing Corporation

تاريخ النشر

2018-10-21

دولة النشر

مصر

عدد الصفحات

6

التخصصات الرئيسية

الأحياء

الملخص EN

Objective.

Systemic lupus erythematosus (SLE) is an autoimmune systemic disease and its pathogenesis has not yet been completely clarified.

Patients with SLE show a deranged lipid metabolism, which can contribute to the immunopathogenesis of the disease and to the accelerated atherosclerosis.

Resolvin D1 (RvD1), a product of the metabolism of the omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA), acts as a specialized proresolving mediator which can contribute in restoring the homeostasis in inflamed tissues.

The aim of the present pilot study is to evaluate plasma levels of RvD1 in patients with SLE and healthy subjects, investigating its potential role as a biomarker of SLE and assessing its relationship with disease activity and laboratory parameters.

Methods.

Thirty patients with SLE and thirty age- and sex-matched healthy subjects (HSs) have been consecutively recruited at Campus Bio-Medico University Hospital.

RvD1 plasma levels were measured by ELISA according to the manufacturer’s protocol (Cayman Chemical Co.).

RvD1 levels were compared using Mann–Whitney test.

Discriminatory ability for SLE has been evaluated by the area under the ROC curve.

Results.

Lower levels of RvD1, 45.6 (35.5–57.4) pg/ml, in patients with SLE have been found compared to HSs, 65.1 (39.43–87.95) pg/ml (p=0.0043).

The area under the ROC curve (AUC) for RvD1 was 0.71 (95% CI: 0.578–0.82) and the threshold value of RvD1 for the classification of SLE was <58.4 pg/ml, sensitivity 80% (95% CI: 61.4–92.3), and specificity 63.3% (95% CI: 43.9–80.1), likelihood ratio 2.2 (95% CI: 1.3–3.6).

Conclusions.

The present preliminary study allows hypothesizing a dysregulation of RvD1 in patients with SLE, confirming the emerging role of bioactive lipids in this disease.

نمط استشهاد جمعية علماء النفس الأمريكية (APA)

Navarini, Luca& Bisogno, Tiziana& Margiotta, Domenico Paolo Emanuele& Piccoli, Alessandra& Angeletti, Silvia& Laudisio, Alice…[et al.]. 2018. Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results. Journal of Immunology Research،Vol. 2018, no. 2018, pp.1-6.
https://search.emarefa.net/detail/BIM-1192566

نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)

Navarini, Luca…[et al.]. Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results. Journal of Immunology Research No. 2018 (2018), pp.1-6.
https://search.emarefa.net/detail/BIM-1192566

نمط استشهاد الجمعية الطبية الأمريكية (AMA)

Navarini, Luca& Bisogno, Tiziana& Margiotta, Domenico Paolo Emanuele& Piccoli, Alessandra& Angeletti, Silvia& Laudisio, Alice…[et al.]. Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results. Journal of Immunology Research. 2018. Vol. 2018, no. 2018, pp.1-6.
https://search.emarefa.net/detail/BIM-1192566

نوع البيانات

مقالات

لغة النص

الإنجليزية

الملاحظات

Includes bibliographical references

رقم السجل

BIM-1192566